AI 5 million enables lung cancer signs, initial diagnosis capable
Using Artificial Intelligence, the new technology operated 5 million chest X-rays in more than 20 countries, which helped early 50,000 people to an early signs of lung cancer. This low -cost method helps doctors to find cancer faster.
In short
- AI saw the signs of lung cancer by screening 5 million people’s chest X-rays
- More than 50,000 people had early signs of lung cancer
- New AI facility is one step ahead in preventive healthcare
A new technology examined the chest X-rays of 5 million people in 20 countries and successfully detected early signs of lung cancer using artificial intelligence.
AII algorithm, developed through a collaboration between Astrazenca and Indian Health -Technical Company Qure.AI, analyzed the scan done in Asia, Middle East, Africa and Latin America – areas where access to advanced clinical devices are often limited.
Astrazheneka, a global bioframacutical company with a headquarters in the UK, is known for developing life-saving treatment in oncology, heart and respiratory diseases. It participated with Qure.Aai, so that they could deploy the AI tool in the resource-granting settings, so that the initial cancer can be more accessible than the detection.
The screening program used Qure.Ai’s ownership algorithm, QXR, which analyzed chest X-rays to identify abnormalities, especially high-risk lung nodules that could indicate early stage cancer.
AI then flagged off these cases for a follow-up diagnostic test like CT scan. So far, around 50,000 people with suspected nodules have been referred to for further testing, enabling earlier diagnosis and rapid intervention.
“Reaching the five million scan milestones to change cancer’s care is a demonstration of digital innovation power. AI-competent equipment like QXR is proving to be a cost-effective way to screen for lung cancer, where radiologists or advanced imaging facilities cannot be easily available,” TI Haveli said that TI Haveli said that International Oncology is the Deputy Speaker of International Oncology.
Qure.ai CEO Prashant Warrier said that this collaboration has helped to score its AI technology in the real world clinical environment. “This milestone shows how AI can bridge the difference in access to healthcare and strengthen the system through rapid diagnosis,” he said.
Lung cancer has become a major cause of cancer-related deaths worldwide, especially in low and medium-oriented countries. In these areas, where screening programs often decrease, technology such as QXR further provides a promising method.
A recent study presented in the European Lung Cancer Congress 2025 found that QXR successfully identified high -risk nodules in 54.1% of cases, highlighting its utility as a frontline screening tool.
With this, Astrazeneca and Qure.AI are now working with local governments and health agencies to expand the access to the AI-operated screening and bring the diagnosis of lung cancer on time to more weak communities.
